Tumor antigen-Major Histocompatibility Complex (Tumor antigen-MHC complex) (TA-MHC)

Tumor antigen-Major Histocompatibility Complex (TA-MHC) complexes are essential targets in modern oncology, representing the presentation of intracellular tumor-specific or tumor-associated peptides on the cell surface for immune surveillance. These complexes consist of a short peptide fragment derived from proteins like gp100 or MAGE-A4 bound to a Major Histocompatibility Complex (MHC) molecule, typically HLA-A*02:01 in clinical applications. Unlike traditional antibody targets that must be surface proteins, TA-MHC complexes allow the immune system to recognize intracellular oncogenic drivers and neoantigens. Therapeutic intervention involves TCR-engineered T-cells (TCR-Ts) or bispecific T-cell engagers (ImmTACs) that bypass natural immune tolerance to high-affinity targets. While highly effective in specific subsets of patients, these therapies are restricted by the patient's HLA type and the absolute requirement for MHC expression on tumor cells. The primary challenge in targeting TA-MHC complexes is ensuring high specificity to avoid catastrophic cross-reactivity with similar self-peptides found in healthy tissues.

Other names

Peptide-HLA complex (pHLA)HLA-peptide complexTumor-associated antigen-MHC complexNeoantigen-MHC complexMHC-peptide complexHLA-restricted tumor antigen

Drugs targeting these complexes, such as T-cell receptor (TCR)-engineered T-cells or bispecific T-cell engagers (ImmTACs), bind specifically to the tumor-derived peptide presented by the MHC molecule. This engagement redirects and activates T-cells to release cytotoxic molecules like perforin and granzymes, leading to the apoptosis of the targeted cancer cell.